[
  {
    "ts": null,
    "headline": "Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study",
    "summary": "Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows and eyelashes at Week 36. Findings from the Phase 3 BRAVE-AA-PEDS study were presented in a late-breaker presentation at the American Academy of Dermatology (AAD) Annual Meeting taking place March",
    "url": "https://finnhub.io/api/news?id=91db7058ce90ef1474732e0a911e999897a595753ced527305b30c52abfbf2bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741456800,
      "headline": "Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study",
      "id": 133193446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows and eyelashes at Week 36. Findings from the Phase 3 BRAVE-AA-PEDS study were presented in a late-breaker presentation at the American Academy of Dermatology (AAD) Annual Meeting taking place March",
      "url": "https://finnhub.io/api/news?id=91db7058ce90ef1474732e0a911e999897a595753ced527305b30c52abfbf2bb"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura速) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting",
    "summary": "WILMINGTON, Del., March 08, 2025--Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura速) in Patients with Prurigo Nodularis (PN)",
    "url": "https://finnhub.io/api/news?id=9c1c928987747a06d29db96268c472b20a5fbbbe9b41edb1f4a37c115e7d752f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741442460,
      "headline": "Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura速) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting",
      "id": 133193447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., March 08, 2025--Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura速) in Patients with Prurigo Nodularis (PN)",
      "url": "https://finnhub.io/api/news?id=9c1c928987747a06d29db96268c472b20a5fbbbe9b41edb1f4a37c115e7d752f"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% in Patients with Prurigo Nodularis at 2025 American Academy of Dermatology Annual Meeting",
    "summary": "Incyte announced results from its pivotal Phase 3 TRuE-PN clinical trial program -TRuE-PN1 and TRuE-PN2 studies - evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% , a topical...",
    "url": "https://finnhub.io/api/news?id=8a36f6a659abc7e2163726b28ad96b56e2df75579d4eda2d99b09a4699d6af87",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741424460,
      "headline": "Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% in Patients with Prurigo Nodularis at 2025 American Academy of Dermatology Annual Meeting",
      "id": 133106844,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "Incyte announced results from its pivotal Phase 3 TRuE-PN clinical trial program -TRuE-PN1 and TRuE-PN2 studies - evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% , a topical...",
      "url": "https://finnhub.io/api/news?id=8a36f6a659abc7e2163726b28ad96b56e2df75579d4eda2d99b09a4699d6af87"
    }
  }
]